Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itano

Showing results (931-940 of 958) with videos related to

Pageof 96
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2021
The membrane-linked adaptor FRS2β fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesisYasuto Takeuchi, Natsuko Kimura, Takahiko Murayama, et al.
BMC Cancer|July 25, 2020
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)Osamu Itano, Yusuke Takemura, Norihiro Kishida, et al.
Journal of Medicinal Chemistry|August 20, 2015
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3Justin K Murray, Yi-Xin Qian, Benxian Liu, et al.
Oncology Letters|July 9, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practiceShigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Scientific Reports|May 13, 2024
Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinomaRyosuke Kasuga, Nobuhito Taniki, Po-Sung Chu, et al.
Frontiers in Immunology|February 21, 2022
Regulation of Peripheral Inflammation by a Non-Viable, Non-Colonizing Strain of Commensal BacteriaKritika Ramani, Taylor Cormack, Adam N R Cartwright, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinomaTakanori Ito, Shigeo Shimose, Joji Tani, et al.
Molecular Therapy. Nucleic Acids|January 6, 2025
Discovery and characterization of stereodefined PMO-gapmers targeting tauKunihiko Kanatsu, Yoshinori Takahashi, Tetsuya Sakaguchi, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5Victor J Cee, Mike Frohn, Brian A Lanman, et al.
Plos One|September 25, 2024
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapyIssei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.
Pageof 96

Showing results (931-940 of 958) with videos related to

Sort By:
Pageof 96
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2021
The membrane-linked adaptor FRS2β fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesisYasuto Takeuchi, Natsuko Kimura, Takahiko Murayama, et al.
BMC Cancer|July 25, 2020
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)Osamu Itano, Yusuke Takemura, Norihiro Kishida, et al.
Journal of Medicinal Chemistry|August 20, 2015
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3Justin K Murray, Yi-Xin Qian, Benxian Liu, et al.
Oncology Letters|July 9, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practiceShigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Scientific Reports|May 13, 2024
Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinomaRyosuke Kasuga, Nobuhito Taniki, Po-Sung Chu, et al.
Frontiers in Immunology|February 21, 2022
Regulation of Peripheral Inflammation by a Non-Viable, Non-Colonizing Strain of Commensal BacteriaKritika Ramani, Taylor Cormack, Adam N R Cartwright, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinomaTakanori Ito, Shigeo Shimose, Joji Tani, et al.
Molecular Therapy. Nucleic Acids|January 6, 2025
Discovery and characterization of stereodefined PMO-gapmers targeting tauKunihiko Kanatsu, Yoshinori Takahashi, Tetsuya Sakaguchi, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5Victor J Cee, Mike Frohn, Brian A Lanman, et al.
Plos One|September 25, 2024
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapyIssei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.
Pageof 96